Abstract

Bausch Health Companies Inc will report quarterly results after market close (Post-Mkt) on July 29, 2026, with consensus pointing to revenue of 2.66 billion US dollars, adjusted EPS of 1.01, and EBIT of 760.50 million, while the market watches whether operating leverage can sustain EBIT growth outpacing sales.

Market Forecast

Consensus expects Bausch Health Companies Inc to deliver revenue of 2.66 billion US dollars, up 7.01% year over year, adjusted EPS of 1.01, up 7.17% year over year, and EBIT of 760.50 million US dollars, up 15.98% year over year; management did not provide explicit gross margin or net margin guidance in the prior update. The company’s main commercial engines are concentrated in Bausch + Lomb/International and Salix, which together supplied the majority of last quarter’s sales and underpin the quarter’s outlook for stable growth and expanding operating efficiency. The most promising segment in the near term is Salix, which generated 639.00 million US dollars last quarter; year-over-year growth for this segment was not disclosed in the publicly available materials, but volume and mix dynamics make it the focal point for incremental profit contribution.

Last Quarter Review

Bausch Health Companies Inc reported revenue of 2.52 billion US dollars, up 11.73% year over year, a gross profit margin of 70.76%, a GAAP net loss attributable to shareholders of 1.42 billion US dollars with a net profit margin of -56.38%, and adjusted EPS of 0.78, up 30.00% year over year. A notable financial highlight was EBIT of 777.00 million US dollars, which increased 32.37% year over year, indicating meaningful operating leverage. By business line, Bausch + Lomb/International contributed 1.53 billion US dollars, Salix contributed 639.00 million US dollars, Diversified Products contributed 185.00 million US dollars, and Solta Medical contributed 171.00 million US dollars; segment-level year-over-year growth rates were not disclosed in the available summary, but the mix was skewed to the two largest franchises that are central to the upcoming quarter’s setup.

Current Quarter Outlook

Main Commercial Engine: Bausch + Lomb/International

Bausch + Lomb/International remains the anchor for aggregate sales, and last quarter’s 1.53 billion US dollars contribution sets a high baseline for the period to be reported. Given the breadth of this franchise, quarter-to-quarter performance typically follows a balanced mix of volume, product mix, and geographic contributions, with pricing and currency acting as ancillary swing factors. For the current quarter, consensus implies that top-line growth can continue while operating efficiency keeps pace, which would be consistent with EBIT outgrowing sales. If the gross margin profile holds near last quarter’s level, the revenue mix in this franchise should help preserve consolidated margin stability even if certain subcategories face normalization after a stronger start to the year. The key watch items are channel inventories and geographic demand dispersion, especially in ex-US markets where currency and procurement cycles can introduce volatility; however, the breadth of the portfolio provides a cushion against idiosyncratic category moves, supporting low-to-mid single-digit growth with modest positive operating leverage.

Most Promising Near-Term Growth Driver: Salix

Salix delivered 639.00 million US dollars last quarter and stands out as the most likely source of incremental margin in the current print due to its attractive mix characteristics. In periods when prescription growth and compliance trends are steady, this business tends to translate modest volume improvement into outsized EBIT contribution, as fixed costs are largely absorbed and gross margin accretion filters down to operating profit. The consensus configuration for this quarter—revenue up 7.01% year over year with EBIT up 15.98%—is consistent with a scenario in which Salix contributes to operating margin expansion relative to last year. The set-up also benefits from disciplined commercial spending phasing, which helps keep SG&A growth below revenue growth for this business line, even as promotional intensity calibrates to competitive dynamics. While segment-level year-over-year growth rates were not disclosed in last quarter’s summary, the current expectation of EBIT growing faster than sales suggests that Salix’s contribution margin will be a focal point for both the headline EPS result and the initial management commentary post-release.

What Will Move the Stock: Margin Capture, Cash Generation, and Mix

The single most consequential variable for the stock this quarter is whether margin momentum can be sustained, given consensus modeling EBIT up 15.98% on revenue up 7.01%. Delivering on this spread would demonstrate that cost controls and mix-sensitive pricing are translating into real operating leverage, which is central to the equity narrative. Gross margin resilience near last quarter’s 70.76% would help, but the more visible swing factor is opex discipline—particularly whether SG&A scales below the top line while R&D remains targeted to high-ROI programs. On cash generation, investors will gauge whether working-capital timing and capital-expenditure discipline support a trajectory consistent with incremental deleveraging; even without giving explicit guidance, clarity on cash conversion can influence sentiment around balance sheet flexibility. Revenue mix is the third lever: outperformance in higher-margin franchises such as Salix can offset normalization in other categories and drive positive EPS variance, while a less favorable mix would temper the EBIT delta implied by consensus. Finally, while currency movements and procurement cycles in international markets can create noise, the breadth of the portfolio provides diversification that typically smooths these effects over the quarter.

Analyst Opinions

Bullish views form the clear majority among identifiable directional previews in the period reviewed, with bullish outnumbering bearish by a wide margin (bullish 100%, bearish 0%), and the constructive case centers on a consistent theme: EBIT growing faster than sales signals improving quality of earnings and a path to steadier cash conversion. The supportive side of the Street emphasizes three points aligned with the consensus numbers for the upcoming report: first, the 7.01% year-over-year revenue growth expectation appears achievable given last quarter’s 1.53 billion US dollars contribution from Bausch + Lomb/International and 639.00 million US dollars from Salix; second, the 15.98% year-over-year EBIT growth estimate suggests tangible operating leverage, underpinned by stable gross margin and measured opex growth; and third, the 7.17% expected increase in adjusted EPS to 1.01 reflects incremental mix benefits flowing through to the bottom line. Pro-bull arguments also underscore that a string of in-line to modestly better quarters could re-anchor expectations around stable mid-single-digit sales growth and high-single-digit EPS growth, creating room for upside if management’s cost actions continue to hold. That cohort also points to the potential for near-term cash generation improvement as working-capital phasing normalizes in the second half, which would reinforce confidence in the company’s capacity to sustain investments while gradually strengthening the balance sheet. In short, the bullish stance is not predicated on outsized top-line acceleration, but rather on credible execution that converts steady demand into improving operating efficiency, with Salix’s mix the incremental catalyst for upside to the EBIT-to-revenue growth spread implied by consensus.